Please ensure Javascript is enabled for purposes of website accessibility

Keep Your Eye on These 4 Healthcare Stocks

By Chris Knight - Updated Aug 23, 2019 at 2:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The growing eye industry is something investors can’t ignore.

Healthcare research is laying the groundwork for drug technology that has never been seen before. By improving product efficacy and safety, as well as patient convenience and compliance, drugs are becoming more sophisticated with every passing year.

Novel drug delivery technologies must overcome many obstacles including frequency of administration, drug resistance, and patient changes in cellular processes over time. Despite the difficulties, these delivery systems are being advanced all the time by a variety of healthcare companies, with each moving along at varying rates. Being conscious of which companies are successful in capitalizing on innovative ways to administer drugs could be extremely important to future growth for your portfolio. These four stocks are leading the way in these exact advancements.

A doctor giving a patient an eye exam

Image Source: Getty Image

Staying focused on what matters

EyePoint Pharmaceuticals (EYPT -5.50%) is one company that has successfully had many drugs approved. Its Durasert is a miniaturized, injectable, sustained-release microinsert that treats a list of ailments. EyePoint also boasts Verisome technology in its portfolio, which is a gradually degrading liquid-gel formulation designed to last up to one year and is currently being used in cataract surgeries to completely eliminate postoperative inflammation drop regimens.

Healthcare investors would do well to look beyond the drug and what it treats, to also notice the potential of its delivery technology. Drug companies are not just creating new drugs for the untreatable, but they are also perfecting new methods themselves that can have a ton to do with how it triumphs in the market.

Kala Therapeutics' (KALA -21.57%) has made advancements in mucus-penetration, recently launching an inflammation treating eye drop that replaces the standard treatment of care from up to 70 drops per month to less than 15.

Ocular Therapeutics (OCUL -5.49%) saw its proprietary tear duct insert using hydrogel technology approved on June 21 for inflammation and pain following ocular surgery-a huge progression for drug delivery technology.

Six months leading to Yutiq's FDA approval, EyePoint Pharmaceuticals' drug that utilizes its Durasert technology to treat chronic non-infectious uveitis affecting the posterior segment of the eye, saw its stock price gain more than 124%, reaching $3.54 per share. Dextenza, which is Ocular Therapeutics' tear duct insert, nudged its stock price 19% higher in that same timespan.

Don't lose sight of the big picture

Although the U.S. is the leader in most healthcare sectors, it's beneficial to step back and see what other plays are being made by the international community. The global ophthalmic drug market size was valued at more than $30 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 4.5% by 2026, according to A Data Book: Healthcare spending and the Medicare program, and the world's largest healthcare companies are already responding to this growth. This year, Novartis (NVS 1.34%) announced the spin-off of its eye division Alcon (ALC -0.20%), creating a separate stand-alone publicly traded company allowing shareholders to benefit by focusing on each of the company's specific pipelines, including Alcon's stronghold on its eye-oriented pipeline. 

Combined with the swelling aging population in the U.S and the 44.57 million Medicare recipients over the age of 65, it's obvious that eye treatment drugs and their delivery systems are becoming exceedingly important and a focal point for any healthcare investor's watchlist. Since a large portion of ophthalmology patients are Medicare beneficiaries, the market has a natural resistance to a recession, making these trends a no-brainer to recognize and follow closely.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocular Therapeutix, Inc. Stock Quote
Ocular Therapeutix, Inc.
OCUL
$3.10 (-5.49%) $0.18
Kala Pharmaceuticals, Inc. Stock Quote
Kala Pharmaceuticals, Inc.
KALA
$0.48 (-21.57%) $0.13
EyePoint Pharmaceuticals, Inc. Stock Quote
EyePoint Pharmaceuticals, Inc.
EYPT
$9.11 (-5.50%) $0.53
Alcon, Inc. Stock Quote
Alcon, Inc.
ALC
$73.28 (-0.20%) $0.15
Novartis AG Stock Quote
Novartis AG
NVS
$91.93 (1.34%) $1.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.